Intestinal Permeability, Irritable Bowel Syndrome with Constipation, and the Role of Sodium-Hydrogen Exchanger Isoform 3 (NHE3)

被引:0
|
作者
Lacy, Brian E. [1 ]
Rosenbaum, David [2 ]
Edelstein, Susan [2 ]
Kozuka, Kenji [2 ]
Williams, Laura A. [2 ]
Kunkel, David C. [3 ]
机构
[1] Mayo Clin, Div Gastroenterol & Hepatol, Davis Bldg,4500 San Pablo Rd, Jacksonville, FL 32224 USA
[2] Ardelyx Inc, Waltham, MA USA
[3] Univ Calif San Diego, Div Gastroenterol, La Jolla, CA USA
来源
CLINICAL AND EXPERIMENTAL GASTROENTEROLOGY | 2024年 / 17卷
关键词
tenapanor; abdominal pain; leaky gut; gut permeability; IBS-C; tight junction protein; transepithelial resistance; PREVALENCE; INFLAMMATION; MANAGEMENT; GUIDELINE; TENAPANOR; SYMPTOMS; HABIT; PAIN;
D O I
10.2147/CEG.S455101
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Increased intestinal permeability has been identified as one of the many pathophysiological factors associated with the development of irritable bowel syndrome (IBS), a common disorder of gut-brain interaction. The layer of epithelial cells that lines the intestine is permeable to a limited degree, and the amount of paracellular permeability is tightly controlled to enable the absorption of ions, nutrients, and water from the lumen. Increased intestinal permeability to macromolecules can be triggered by a variety of insults, including infections, toxins from food poisoning, or allergens, which in turn cause an inflammatory response and are associated with abdominal pain in patients with IBS. This review article discusses increased intestinal permeability in IBS, focusing on IBS with constipation (IBS-C) through the lens of a patient case with a reported prior diagnosis of "leaky gut syndrome" upon initial contact with a gastrointestinal specialist. We review advantages and disadvantages of several methods of measuring intestinal permeability in patients and discuss when measuring intestinal permeability is appropriate in the therapeutic journey of patients with IBS-C. Furthermore, we discuss a possible mechanism of restoring the intestinal barrier to its healthy state through altering intracellular pH by inhibiting sodium-hydrogen exchanger isoform 3 (NHE3). Tenapanor is a minimally absorbed, small-molecule inhibitor of NHE3 that has been approved by the US Food and Drug Administration for the treatment of IBS-C in adults. Preclinical studies showed that tenapanor may restore the intestinal barrier in IBS-C by affecting the conformation of tight junction proteins via NHE3 inhibition to block the paracellular transport of macromolecules from the intestinal lumen. Testing for increased permeability in patients with IBS-C who experience abdominal pain may help inform the choice of therapeutics and alter patients' misconceptions about "leaky gut syndrome".
引用
收藏
页码:173 / 183
页数:11
相关论文
共 14 条
  • [1] Long-term safety of tenapanor in patients with irritable bowel syndrome with constipation in the T3MPO-3 study
    Lembo, Anthony J.
    Friedenberg, Keith A.
    Fogel, Ronald P.
    Edelstein, Susan
    Zhao, Suling
    Yang, Yang
    Rosenbaum, David P.
    Chey, William D.
    NEUROGASTROENTEROLOGY AND MOTILITY, 2023, 35 (11)
  • [2] Linaclotide in irritable bowel syndrome with constipation: A Phase 3 randomized trial in China and other regions
    Yang, Yunsheng
    Fang, Jingyuan
    Guo, Xiaozhong
    Dai, Ning
    Shen, Xizhong
    Yang, Youlin
    Sun, Jing
    Bhandari, Bal Raj
    Reasner, David S.
    Cronin, Jacquelyn A.
    Currie, Mark G.
    Johnston, Jeffrey M.
    Zeng, Peter
    Montreewasuwat, Niwat
    Chen, George Zhijian
    Lim, Sam
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 (05) : 980 - 989
  • [3] Effectivity and safety profile of tenapanor, a sodium-hydrogen exchanger isoform 3 inhibitor, as an innovative treatment for hyperphosphatemia in chronic kidney disease: A systematic review of clinical studies
    Suciangto, William
    Rasyid, Haerani
    Vicente, Anastasya Angelica
    Suciangto, Winny
    NEFROLOGIA, 2024, 44 (06): : 796 - 806
  • [4] Stool and urine trefoil factor 3 levels: associations with symptoms, intestinal permeability, and microbial diversity in irritable bowel syndrome
    Heitkemper, M. M.
    Cain, K. C.
    Shulman, R. J.
    Burr, R. L.
    Ko, C.
    Hollister, E. B.
    Callen, N.
    Zia, J.
    Han, C. J.
    Jarrett, M. E.
    BENEFICIAL MICROBES, 2018, 9 (03) : 345 - 355
  • [5] Role of Sodium-Hydrogen Exchanger-1 (NHE-1) in the Effect of Exercise on Intermittent Hypoxia-Induced Left Ventricular Dysfunction
    Chen, Michael Yu-Chih
    Yang, Kun-Ta
    Shen, Yan-Jhih
    Cheng, Ching-Feng
    Tu, Wei-Chia
    Chen, Tsung-I
    CHINESE JOURNAL OF PHYSIOLOGY, 2015, 58 (04): : 254 - 262
  • [6] Safety and tolerability of linaclotide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation: pooled Phase 3 analysis
    Nee, Judy W.
    Johnston, Jeffrey M.
    Shea, Elizabeth P.
    Walls, Courtney E.
    Tripp, Kenneth
    Shiff, Steven
    Fox, Susan M.
    Bochenek, Wieslaw
    Weissman, Darren
    Currie, Mark G.
    Lembo, Anthony J.
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2019, 13 (04) : 397 - 406
  • [7] Obesity Is Inversely Related to Hydrogen-Producing Small Intestinal Bacterial Overgrowth in Non-Constipation Irritable Bowel Syndrome
    Jung, Seung-Eun
    Joo, Nam-Seok
    Han, Kyung-Sun
    Kim, Kyu-Nam
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2017, 32 (06) : 948 - 953
  • [8] Probiotic VSL#3 Treatment Reduces Colonic Permeability and Abdominal Pain Symptoms in Patients With Irritable Bowel Syndrome
    Boonma, Prapaporn
    Shapiro, Jordan M.
    Hollister, Emily B.
    Badu, Shyam
    Wu, Qinglong
    Weidler, Erica M.
    Abraham, Bincy P.
    Devaraj, Sridevi
    Luna, Ruth Ann
    Versalovic, James
    Heitkemper, Margaret M.
    Savidge, Tor C.
    Shulman, Robert J.
    FRONTIERS IN PAIN RESEARCH, 2021, 2
  • [9] Plecanatide Improves Symptoms of Irritable Bowel Syndrome with Constipation: Results of an Integrated Efficacy and Safety Analysis of Two Phase 3 Trials
    Brenner, Darren M.
    Dorn, Spencer
    Fogel, Ronald P.
    Christie, Jennifer
    Laitman, Adam P.
    Rosenberg, Jonathan
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2023, 16 : 3769 - 3777
  • [10] Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials
    Brenner, Darren M.
    Fogel, Ronald
    Dorn, Spencer D.
    Krause, Richard
    Eng, Paul
    Kirshoff, Robert
    Nguyen, Anhthu
    Crozier, Robert A.
    Magnus, Leslie
    Griffin, Patrick H.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 (05) : 735 - 745